CareDx, Inc. Stock 12‑Month Price Target Raised to $86.17, Implies 20% Upside

CareDx, Inc.'s average stock price target increased to $86.17 from $65.33, with estimates ranging from $46 to $100 per share. This implies a 20% upside based on the Oct. 29 closing price. The consensus rating remains 'Buy' among 7 analysts, with 5 Buys and 2 Holds.

Original reporting
Published Oct 30, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 1:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CareDx, Inc. Stock 12‑Month Price Target Raised to $86.17, Implies 20% Upside — source image
Decision brief

The 30-second read

$CDNABullishLow
01

Why it matters

Analyst consensus remains a Buy, reinforcing the positive outlook.

02

Market read

Analyst price target upgrade may attract short-term buying interest.

03

What to watch

No new product or trial news accompanies the target raise.

Relevance 6/10Novelty 6/10Timing: today

Background

CareDx is a molecular diagnostics company focused on transplant monitoring.

Company-level read

Ticker impact

$CDNABullishMedium confidence
Context

Analysts raised CareDx's average price target to $86.17, implying ~20% upside.

Expected impact

upward pressure as investors price in the higher target.

Evidence & confidence

The new target reflects improved analyst outlook; no new fundamentals disclosed.

Market effects

May lift sentiment in the biotech diagnostics sector.

Limited to U.S. biotech investors.

Minimal global impact.

Counterpoint

Target could be premature if upcoming trial data disappoints.

Key entities

  • CareDx, Inc.

    Molecular diagnostics firm.

Related articles

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.